Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева
Yu.V.Bykov1, R.A.Bekker2 1 Stavropol State Medical University of the Ministry of Health of the Russian Federation. 355017, Russian Federation, Stavropol, ul. Mira, d. 310; 2 David Ben-Gurion University in Negev. 8410501, Israel, Be'er-Sheva
Список исп. литературыСкрыть список 1. Аведисова А.С., Чахава К.О., Ершова Е.М. Иксел при терапии больных с депрессивным расстройством и неврологически обусловленным хроническим болевым синдромом. Психиатрия и психофармакотерапия (Журнал им. П.Б.Ганнушкина). 2005; 7 (3): 144–8. / Avedisova A.S., Chakhava K.O., Ershova E.M. Iksel pri terapii bol'nykh s depressivnym rasstroistvom i nevrologicheski obuslovlennym khronicheskim bolevym sindromom. Psikhiatriia i psikhofarmakoterapiia (Zhurnal im. P.B.Gannushkina). 2005; 7 (3): 144–8. [in Russian] 2. Истомина О.И. Лекарственно-индуцированная головная боль (клинико-психо-нейрофизиологический анализ). Автореф. … канд. мед. наук. М., 2011. / Istomina O.I. Lekarstvenno-indutsirovannaia golovnaia bol' (kliniko-psikho-neirofiziologicheskii analiz). Avtoref. … kand. med. nauk. M., 2011. [in Russian] 3. Истомина О.И., Филатова Е.Г. Лечение хронической ежедневной головной боли. Клин. неврология. 2011; 1: 30–5. / Istomina O.I., Filatova E.G. Lechenie khronicheskoi ezhednevnoi golovnoi boli. Klin. nevrologiia. 2011; 1: 30–5. [in Russian] 4. Каспер С. Место иксела в лечении депрессии. Соц. и клин. психиатрия. 2005; 2 (15): 45–50. / Kasper S. Mesto iksela v lechenii depressii. Sots. i klin. psikhiatriia. 2005; 2 (15): 45–50. [in Russian] 5. Линец Ю.П., Косинский В.П. Мильнаципрана гидрохлорид (иксел) в комплексной терапии больных с тревожными и депрессивными расстройствами. Вестн. Санкт-Петербургского ун-та. Серия 11. Медицина. 2008; 3: 65–9. / Linets Iu.P., Kosinskii V.P. Mil'natsiprana gidrokhlorid (iksel) v kompleksnoi terapii bol'nykh s trevozhnymi i depressivnymi rasstroistvami. Vestn. Sankt-Peterburgskogo un-ta. Seriia 11. Meditsina. 2008; 3: 65–9. [in Russian] 6. Селицкий Г.В., Каприн А.Д., Извозчиков С.Б. и др. Милнаципран (Иксел) в лечении тревожно-депрессивных и сексуальных расстройств у больных с невоспалительным синдромом хронической тазовой боли. Терапевт. архив. 2007; 5 (79): 81–4. / Selitskii G.V., Kaprin A.D., Izvozchikov S.B. i dr. Milnatsipran (Iksel) v lechenii trevozhno-depressivnykh i seksual'nykh rasstroistv u bol'nykh s nevospalitel'nym sindromom khronicheskoi tazovoi boli. Terapevt. arkhiv. 2007; 5 (79): 81–4. [in Russian] 7. Табеева Г.Р., Азимова Ю.Э. Опыт применения милнаципрана в лечении синдрома хронической ежедневной головной боли. Рос. журн. боли. 2006; 3 (12): 30–6. / Tabeeva G.R., Azimova Iu.E. Opyt primeneniia milnatsiprana v lechenii sindroma khronicheskoi ezhednevnoi golovnoi boli. Ros. zhurn. boli. 2006; 3 (12): 30–6. [in Russian] 8. Фурсов Б.Б. Милнаципран (иксел): некоторые аспекты применения в общей медицине (обзор литературы). Психические расстройства в общей медицине. 2009; 2: 63–5. / Fursov B.B. Milnatsipran (iksel): nekotorye aspekty primeneniia v obshchei meditsine (obzor literatury). Psikhicheskie rasstroistva v obshchei meditsine. 2009; 2: 63–5. [in Russian] 9. Хлистовская Н.Г. Клинико-эпидемиологическая характеристика хронической распространенной боли у лиц с аффективной патологией и ее коррекции антидепрессантами. Автореф. ... канд. мед. наук. СПб., 2007. / Khlistovskaia N.G. Kliniko-epidemiologicheskaia kharakteristika khronicheskoi rasprostranennoi boli u lits s affektivnoi patologiei i ee korrektsii antidepressantami. Avtoref. ... kand. med. nauk. SPb., 2007. [in Russian] 10. Чахава К.О. Милнаципран – антидепрессант с аналгезирующим эффектом (обзор литературы). Психические расстройства в общей медицине. 2009; 3: 28–32. / Chakhava K.O. Milnatsipran – antidepressant s analgeziruiushchim effektom (obzor literatury). Psikhicheskie rasstroistva v obshchei meditsine. 2009; 3: 28–32. [in Russian] 11. Шмуклер А.Б. Применение препарата Иксел (милнаципран) в клинической практике. Соц. и клин. психиатрия. 2003; 1 (13): 170–3. / Shmukler A.B. Primenenie preparata Iksel (milnatsipran) v klinicheskoi praktike. Sots. i klin. psikhiatriia. 2003; 1 (13): 170–3. [in Russian] 12. Abtroun L, Bunouf P, Gendreau RM, Vitton O. Is the Efficacy of Milnacipran in Fibromyalgia Predictable? A Data-Mining Analysis of Baseline and Outcome Variables. Clin J Pain 2016; 32 (5): 435–40. 13. Amelin A.V., Tarasova S.V., Ignatov Iu.D. et al. Antidepressants with different action mechanisms in the treatment of chronic daily headache. [Article in Russian]. Zh Nevrol Psikhiatr Im S.S.Korsakova. 2007; 107 (9): 38–44. 14. Ang DC, Jensen MP, Steiner JL et al. Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial. Clin J Pain 2013; 29 (9): 747–54. 15. Arnold LM, Palmer RH, Hufford MR, Chen W. Effect of milnacipran on body weight in patients with fibromyalgia. Int J Gen Med 2012; 5: 879–87. 16. Bateman L, Palmer RH, Trugman JM, Lin Y. Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. J Pain Res 2013; 6: 311–8. 17. Bernstein CD, Albrecht KL, Marcus DA. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium. Expert Opin Pharmacother 2013; 14 (7): 905–16. 18. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 2004; 19 (Suppl. 1): S21–5. 19. Brown C, Bachmann G, Foster D et al. Milnacipran in provoked vestibulodynia: efficacy and predictors of treatment success. J Low Genit Tract Dis 2015; 19 (2): 140–4. 20. Carville SF, Arendt-Nielsen S et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67: 536–41. 21. Chalana H. A case report of Milnacipran in phantom-limb pain. Asian J Psychiatr 2010; 3 (3): 155–6. 22. Clauw DJ, Mease P, Palmer RH et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [published correction appears in Clin Ther 2009; 31 (2): 446]. Clin Ther 2008; 30 (11): 1988–2004. 23. Clauw DJ, Mease PJ, Palmer RH et al. Continuing efficacy of milnacipran following long–term treatment in fibromyalgia: a randomized trial. Arthritis Res Ther 2013; 15 (4): R88. 24. Cording M, Derry S, Phillips T et al. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev 2015; 10: CD008244. 25. Depoortère R, Meleine M, Bardin L et al. Milnacipran is active in models of irritable bowel syndrome and abdominal visceral pain in rodents. Eur J Pharmacol 2011; 672 (1–3): 83–7. 26. Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 7: CD011789. 27. Dworkin RH, O'Connor AB, Backonja M et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237–51. 28. Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology 1995; 83: 1046–54. 29. Engel ER, Kudrow D, Rapoport AM. A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine. Neurol Sci 2014; 35 (3): 429–35. 30. Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109–18. 31. Higuchi T, Briley M. Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan. Neuropsychiatr Dis Treat 2007; 3 (1): 41–58. 32. Hindmarch I, Rigney U, Stanley N, Briley M. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 2000; 49 (2): 118–25. 33. Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ. Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005; 21: 170–7. 34. Hwang AS, Wilcox GL. Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain 1987; 28: 343–55. 35. Ikawa M, Yamada K. Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome. Clin Neuropharmacol 2010; 33 (3): 163–4. 36. Ito M, Kimura H, Yoshida K et al. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol 2010; 33 (2): 79–83. 37. Ito M, Yoshida K, Kimura H et al. Successful treatment of trigeminal neuralgia with milnacipran. Clin Neuropharmacol 2007; 30 (3): 183–5. 38. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 2003; 26: 696–705. 39. Kasper S, Pail G. Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat 2010; 6: 23–31. 40. Kato Y, Sato T, Katagiri A et al. Milnacipran dose-effect study in patients with burning mouth syndrome. Clin Neuropharmacol 2011; 34 (4): 166–9. 41. Kesim M, Yanik MN, Kadioglu M et al. The evaluation of analgesic effects of milnacipran and sertraline in tail-flick test. Bratisl Lek Listy 2014; 115 (1): 3–6. 42. Kim JL, Rele S, Marks DM et al. Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo–controlled, crossover trial. Prim Care Companion CNS Disord 2013; 15 (6); pii: PCC.13m01555. 43. Kimura H, Yoshida K, Ito M et al. Plasma levels of milnacipran and its effectiveness for the treatment of chronic pain in the orofacial region. Hum Psychopharmacol 2012; 27 (3): 322–8. 44. Kito S, Nakajima T, Koga Y. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report. Eur Psychiatry 2005; 20: 355. 45. Kohno T, Kimura M, Sasaki M et al. Milnacipran inhibits glutamatergic N-methyl-D-aspartate receptor activity in spinal dorsal horn neurons. Mol Pain 2012; 8: 45. 46. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 1997; 70: 41–51. 47. Kranzler JD, Gendreau RM. Role and rationale for the use of milnacipran in the management of fibromyalgia. Neuropsychiatr Dis Treat 2010; 6: 197–208. 48. Kumazawa T, Perl ER. Excitation of marginal and substantia gelatinosa neurons in the primate spinal cord: indications of their place in dorsal horn functional organization. J Comp Neurol 1978; 177: 417–34. 49. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997; 13: 189–96. 50. Lee YC, Massarotti E, Edwards RR et al. Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial. J Rheumatol 2016; 43 (1): 38–45. 51. Marks DM, Shah MJ, Patkar AA et al. Serotonin–norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol 2009; 7 (4): 331–6. 52. Marks DM, Bolognesi MP. Open-label milnacipran for patients with persistent knee pain 1 year or longer after total knee arthroplasty: a pilot study. Prim Care Companion CNS Disord 2013; 15 (4); pii: PCC.12m01496; doi: 10.4088/PCC. 53. Matthey A, Cedraschi C, Piguet V et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician 2013; 16 (5): E553–62. 54. Mease PJ, Clauw DJ, Gendreau RM et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double–blind, placebo–controlled trial [published correction appears in J Rheumatol 2009; 36 (3): 661]. J Rheumatol 2009; 36 (2): 398–409. 55. Mease PJ, Farmer MV, Palmer RH et al. Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Ther Adv Musculoskelet Dis 2013; 5 (3): 113–26. 56. Mika J, Zychowska M, Makuch W et al. Neuronal and immunological basis of action of antidepressants in chronic pain – clinical and experimental studies. Pharmacol Rep 2013; 65 (6): 1611–21. 57. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66 (6): 355–474. 58. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 2004; 19 (Suppl. 1): S15–19. 59. Mohr P, Bitter I, Svestka J et al. Management of depression in the presence of pain symptoms. Psychiatr Danub 2010; 22 (1): 4–13. 60. Nagoshi Y, Watanabe A, Inoue S et al. Usefulness of milnacipran in treating phantom limb pain. Neuropsychiatr Dis Treat 2012; 8: 549–53. 61. Nakagawa A, Watanabe N, Omori IM et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; 3: CD006529. 62. Ohnami S, Kato A, Ogawa K et al. Effects of milnacipran, a 5-HT and noradrenaline reuptake inhibitor, on C-fibre-evoked field potentials in spinal long-term potentiation and neuropathic pain. Br J Pharmacol 2012; 167 (3): 537–47. 63. Onal A, Parlar A, Ulker S et al. Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain. Pharmacol Biochem Behav 2007; 88 (2): 171–8. 64. Ormseth MJ, Eyler AE, Hammonds CL, Boomershine CS. Milnacipran for the management of fibromyalgia syndrome. J Pain Res 2010; 3: 15–24. 65. Pae CU. Milnacipran for chronic pain in the orofacial region. Clin Neuropharmacol 2010; 33 (5): 270. 66. Palmer RH, Periclou A, Banerjee P. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia. Ther Adv Musculoskelet Dis 2010; 2 (4): 201–20. 67. Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C 3rd. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 284 (1): 208–14. 68. Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 2002; 17 (Suppl. 1): S25–35. 69. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992; 35 (5): 550–6. 70. Sansone RA, Sansone LA. SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder? Innov Clin Neurosci 2011; 8 (6): 10–4. 71. Serretti A, Chiesa A, Calati R et al. Novel antidepressants and panic disorder: evidence beyond current guidelines. Neuropsychobiology 2011; 63 (1): 1–7. 72. Shimamoto E, Doi N, Suwa H et al. A case of postherpetic neuralgia improved by milnacipran. Jpn J Clin Psychopharmacol 2002; 5: 197–200. 73. Sigurdsson A, Maixner W. Effects of experimental and clinical noxious counterirritants on pain perception. Pain 1994; 57: 265–75. 74. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96: 399–409. 75. South SM, Kohno T, Kaspar BK et al. A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. J Neurosci 2003; 23: 5031–40. 76. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th Ed. Cambridge University Press, 2013. 77. Staud R, Lucas YE, Price DD, Robinson ME. Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial. J Pain 2015; 16 (8): 750–9. 78. Sugimoto K. The dubious effect of milnacipran for the treatment of burning mouth syndrome. Clin Neuropharmacol 2011; 34 (4): 170–3. 79. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends in the Pharmacological Sciences 2004; 2512: 613–7. 80. Tanikawa H. Efficacy of milnacipran in patients with chronic orthopaedic pain including degenerative spondylosis and osteoarthritis. Int J Psychiatr Clin Pract 2002; 6: 255. 81. Toyofuku A, Miyako H. A case of temporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipran. Hum Psychopharmacol 2004; 19: 357–8. 82. Toyofuku A. Efficacy of milnacipran for glossodynia patients. Int J Psychiatry Clin Pract 2003; 7 (Suppl. 1): 23–4. 83. Ukai K, Kimura H, Arao M et al. Effectiveness of low-dose milnacipran for a patient suffering from pain disorder with delusional disorder (somatic type) in the orofacial region. Psychogeriatrics 2013; 13 (2): 99–102. 84. Utsunomiya K, Ukita T, Hirota S. One case of postherpetic neuralgia treated with milnacipran. Jpn J Clin Psychopharmacol 2002; 5: 193–6. 85. Yokogawa F, Kiuchi Y, Ishikawa Y et al. An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg 2002; 95 (1): 163–8. 86. Yoshimura M, Nishi S. Blind patch-clamp recordings from substantia gelatinosa neurons in adult rat spinal cord slices: pharmacological properties of synaptic currents. Neurosci 1993; 53: 519–26.